Notably, the proportion of patients who discontinued treatment due to AEs was higher with semaglutide compared to its comparators (5% to 14% vs
improves with slower dose escalation Vomiting, diarrhea, or constipation Bloating, heartburn, or stomach discomfort Reduced appetite and early fullness Fatigue or headache Less common side effects Injection-site reactions Fatigue or changes in taste Temporary mild hair thinning (limited evidence) Serious but rare risks Pancreatitis seek care immediately if you experience severe abdominal pain Gallbladder disease or gallstones Kidney complications, particularly from dehydration Thyroid C-cell tumor risk in patients with medullary thyroid cancer history or MEN2 Low blood sugar when combined with insulin or sulfonylureas Contact your provider immediately if you experience severe or persistent abdominal pain, constant vomiting, signs of dehydration, yellowing of the skin or eyes, or symptoms of low blood sugar
This guide walks through how each compound works, where the evidence is strongest, and how we think about prescribing them at our clinic
doi: 10.1074/jbc.M113.458141
This triple agonist approach distinguishes retatrutide peptide Canada research products from dual agonists such as tirzepatide (GLP-1R/GIPR) and single agonists such as semaglutide (GLP-1R only)
